Blog: Our Insights
Your resource for industry news and updates from Broughton.
Report

Broughton welcomes Paul Hardman as our new Head of Scientific Affairs


May 6, 2021

Published by Dr. Nveed Chaudhary

E-cigarettes, ENDS, PMTA, FDA, Regulations, Next Generation Products, Smoke free future, Vaping

Broughton is delighted to announce that Paul Hardman joins as Head of Scientific Affairs. This latest appointment further bolsters the company’s expansion plans.

We are delighted to welcome Paul Hardman to our team as he takes up the post of Head of Scientific Affairs.

 

Paul has extensive experience in inhaled product development across pharmaceutical, Electronic Nicotine Delivery Systems (ENDS) and consumer products and will help us expand our offer further for clients.

 

At Broughton we have built a reputation for advancing a smoke-free future by helping ENDS companies bring non-combustible products to market – but we know we can do more. That is why we are currently expanding our full-service regulatory consultancy to cover new product categories including modern oral nicotine pouches and cannabis products.  

 

To progress these aims, we have made a series of senior level appointments, with Paul being the latest recruit in our expansion plan.

 

Paul will immediately undertake the task of growing the scientific affairs team further to enable the business to expand and continue to offer a premium consultancy experience for clients in the industry; and he is well placed to do so. He comes to Broughton from the role of scientific lead with Nerudia where he spent the previous five years designing the testing strategy for the chemistry of inhaled and oral next-generation nicotine products, from assessing a variety of prototypes at the early stages of development through to characterization of products for submission through the US Premarket Tobacco Product Application (PMTA) process. 

 

Earlier in his career Paul worked at a specialist pharmaceutical company where he gained experience of dry powder and metered dose inhaler development both for the treatment of local lung conditions and systemic absorption. He also has experience leading the quality control department in a multinational pharmaceutical company involved in the production of generic nicotine lozenges. 

Paul said: “I am passionate about the opportunity to work with multiple clients and really get to the heart of their products so that Broughton can best serve these businesses by championing those points in their regulatory submissions.    

“My role will involve offering scientific and regulatory consultancy to clients and growing the team to enable us to deliver a highly effective offering as Broughton moves into new areas. I am eager to build on the success the business has already achieved.” 

 “By accelerating a smoke-free future, together with our clients, we can help realize global level tobacco harm reduction, and save the lives of the 1 billion people who continue to smoke today.”

 

Image: Paul Hardman

Paul Harman_20210423_111633

 

Need a consultation?

 

Can we help you?

Broughton have deep CRO capabilities and an experienced team of scientific and regulatory professionals to manage full service global regulatory projects. Our knowledge of global regulatory pathways offers significant insights that can be incorporated into your project plans. Our mission is to accelerate safer nicotine-delivery products to market; advancing a smoke-free future.

Book a meeting with us today to discuss your requirements.

 

Contact us

From basic questions to complex compliance inquiries, we're here to help! Contact us today.